PubMed:32082518 JSONTXT

{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":73},"obj":"Sentence"},{"id":"T2","span":{"begin":74,"end":134},"obj":"Sentence"},{"id":"T3","span":{"begin":135,"end":270},"obj":"Sentence"},{"id":"T4","span":{"begin":271,"end":369},"obj":"Sentence"},{"id":"T5","span":{"begin":370,"end":512},"obj":"Sentence"},{"id":"T6","span":{"begin":513,"end":702},"obj":"Sentence"},{"id":"T7","span":{"begin":703,"end":810},"obj":"Sentence"},{"id":"T8","span":{"begin":811,"end":901},"obj":"Sentence"},{"id":"T9","span":{"begin":902,"end":1055},"obj":"Sentence"},{"id":"T10","span":{"begin":1056,"end":1111},"obj":"Sentence"},{"id":"T11","span":{"begin":1112,"end":1247},"obj":"Sentence"},{"id":"T12","span":{"begin":1248,"end":1383},"obj":"Sentence"},{"id":"T13","span":{"begin":1384,"end":1487},"obj":"Sentence"},{"id":"T14","span":{"begin":1488,"end":1642},"obj":"Sentence"},{"id":"T15","span":{"begin":1643,"end":1892},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":73},"obj":"Sentence"},{"id":"T2","span":{"begin":74,"end":134},"obj":"Sentence"},{"id":"T3","span":{"begin":135,"end":270},"obj":"Sentence"},{"id":"T4","span":{"begin":271,"end":369},"obj":"Sentence"},{"id":"T5","span":{"begin":370,"end":512},"obj":"Sentence"},{"id":"T6","span":{"begin":513,"end":702},"obj":"Sentence"},{"id":"T7","span":{"begin":703,"end":810},"obj":"Sentence"},{"id":"T8","span":{"begin":811,"end":901},"obj":"Sentence"},{"id":"T9","span":{"begin":902,"end":1055},"obj":"Sentence"},{"id":"T10","span":{"begin":1056,"end":1111},"obj":"Sentence"},{"id":"T11","span":{"begin":1112,"end":1247},"obj":"Sentence"},{"id":"T12","span":{"begin":1248,"end":1383},"obj":"Sentence"},{"id":"T13","span":{"begin":1384,"end":1487},"obj":"Sentence"},{"id":"T14","span":{"begin":1488,"end":1642},"obj":"Sentence"},{"id":"T15","span":{"begin":1643,"end":1892},"obj":"Sentence"}],"text":"Effect of Lactocare® Synbiotic on Disease Severity in Ulcerative Colitis: A Randomized Placebo-Controlled Double-Blind Clinical Trial.\nBACKGROUND Inflammatory bowel diseases are managed by different methods, which may not be well tolerated because of their side effects. Recently, pro-prebiotics are considered as a supplementary treatment in gastrointestinal diseases. In this study, the effect of Lactocare® (ZistTakhmir Company) was investigated on the disease severity in mild to moderate ulcerative colitis. METHODS In this randomized, double-blind clinical trial (Iranian Registry of Clinical Trials number: IRCT201407271264N5), 60 patients with mild to moderate ulcerative colitis were included. An 8-week trial was carried out comparing Lactocare® as a supplement with standard therapy against placebo. Simple Clinical Colitis Activity Index (SCCAI) was measured at baseline and after 8 weeks. Statistical analysis was performed using paired ttest to assess the temporal changes (before and after the treatment) in the mean of SCCAI in each group. Chi-square test was used to compare the response rates. Odds ratios (OR) and the 95% confidence intervals (95%CI) were also calculated. p values of less than 0.05 were considered significant. RESULTS A significant decreased mean SCCAI was seen in the intervention group (4.56 ± 2.56) vs. placebo group (6.54 ± 2.47) (p \u003c 0.05). Response to treatment was seen in 64.3% of the treatment group vs. 47% in the placebo group (p = 0.18). Response to treatment was observed in 90.9% of patients with ulcerative colitis for more than 5 years compared with 44.4% of the control group (p = 0.01). CONCLUSION Regarding the effectiveness of pre-probiotics in mitigating symptoms in patients with ulcerative colitis, it could be suggested to try pre-probiotics in the standard treatment particularly in those with more than five years ofthe disease."}